

**Amendments to the Claims**

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claims 1-26 (cancelled).

27. (new) A method for inhibiting the action of interleukin 1 (Il-1) for treating neurological disorders in a human by administering an Il-1 inhibitor for reducing the inflammation of neuronal tissue of said human, or for modulating the immune response affecting neuronal tissue of said human, comprising the step of:

a) administering a therapeutically effective dosage level to said human of said Il-1 inhibitor for reducing the inflammation of neuronal tissue of said human, or for modulating the immune response affecting neuronal tissue of said human; and

b) administering said dose either intralesionally or perilesionally.

28. (new) A method for inhibiting the action of Il-1 in accordance with claim 27, wherein said Il-1 inhibitor is selected from the group consisting of Il-1 RA, Il-1R type II, a monoclonal antibody to Il-1, soluble receptors to Il-1 and soluble receptors to Il-1 fused to an Fc immunoglobulin fragment.

29. (new) A method for inhibiting the action of Il-1 in accordance with claim 27, wherein the step of administering said Il-1 inhibitor is performed through local subcutaneous administration for treating an inflammatory condition resulting from cartilage damage.

30. (new) A method for inhibiting the action of Il-1 in accordance with claim 27, wherein the step of administering said Il-1 inhibitor is performed through local subcutaneous administration for treating brain injury as a result of trauma, epilepsy, hemorrhage or stroke.

31. (new) A method for inhibiting the action of Il-1 in accordance with claim 27, wherein the step of administering said Il-1 inhibitor is performed topically for treating an ocular disease.